Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
1,9 CHF | +9,07% | -3,55% | -10,12% |
26/04 | Idorsia krijgt positief advies van EU-geneesmiddelenregulator voor behandeling tegen resistente hypertensie | MT |
11/04 | Zwitserse beursindex daalt nu ECB wijst op renteverlaging in juni | MT |
Vakgebied
Aantal werknemers: 650
Verkoop per activiteit
CHF in miljoen | 2021 | Gewicht | 2022 | Gewicht | Delta |
---|---|---|---|---|---|
Drugs
100,0
%
| 35 | 100,0 % | 97 | 100,0 % | +174,70% |
Verkoop per regio
CHF in miljoen | 2021 | Gewicht | 2022 | Gewicht | Delta |
---|---|---|---|---|---|
Switzerland
48,0
%
| 35 | 100,0 % | 47 | 48,0 % | +31,77% |
Japan
45,3
%
| - | - | 44 | 45,3 % | - |
United States
5,7
%
| - | - | 6 | 5,7 % | - |
Rest of World
1,0
%
| 0 | 0,0 % | 1 | 1,0 % | - |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Jean-Paul Clozel
CEO | Chief Executive Officer | 69 | 01-06-17 |
André Muller
DFI | Director of Finance/CFO | 60 | 01-06-17 |
Martine Clozel
CTO | Chief Tech/Sci/R&D Officer | 68 | 01-06-17 |
Andrew C. Weiss
IRC | Investor Relations Contact | 55 | 01-06-17 |
Alberto Gimona
PRN | Corporate Officer/Principal | 64 | 01-02-19 |
Julien Gander
LAW | General Counsel | 45 | - |
Human Resources Officer | 45 | 01-06-17 | |
Simon Jose
PRN | Corporate Officer/Principal | 58 | 01-12-18 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Jörn Aldag
BRD | Director/Board Member | 65 | 13-05-20 |
Peter Kellogg
BRD | Director/Board Member | 67 | 12-05-21 |
Jean-Paul Clozel
CEO | Chief Executive Officer | 69 | 01-06-17 |
Felix R. Ehrat
BRD | Director/Board Member | 67 | 13-05-20 |
Sandy Mahatme
BRD | Director/Board Member | 59 | 13-05-20 |
Mathieu Simon
CHM | Chairman | 67 | 03-05-19 |
Srishti Gupta
BRD | Director/Board Member | 47 | 12-05-21 |
Director/Board Member | 61 | 04-05-23 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 188 844 867 | 110 902 769 ( 58,73 %) | 9 653 500 ( 5,112 %) | 58,73 % |
Participaties
Naam | Aandelen | % | Totale waarde |
---|---|---|---|
IDORSIA LTD 4.80% | 9 049 500 | 4.80% | 28 413 439 $ |
1 301 128 | 10.31% | 14 113 492 $ |
Bedrijfsgegevens
Bedrijven van de groep
Naam | Categorie en sector |
---|---|
Idorsia Pharmaceuticals Ltd.
Idorsia Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Part of Idorsia Ltd., Idorsia Pharmaceuticals Ltd. is a Swiss company that aims to discover, develop, and provide innovative medicines to patients. The private company is based in Allschwil, Switzerland. The company has created an eBook that provides useful information about Fabry disease, a rare inherited disorder caused by the build-up of a fat-like substance in the cells of the body organs. Jean-Paul Clozel has been the CEO of the company since 2017. |
Pharmaceuticals: Major
|
Sector
Verkoop per regio
Herzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
-10,12% | 371 mln. | |
-2,31% | 103 mld. | |
+0,56% | 95,28 mld. | |
+1,69% | 22,15 mld. | |
-17,37% | 21,02 mld. | |
-9,30% | 18,15 mld. | |
-41,01% | 16,73 mld. | |
-14,85% | 16,05 mld. | |
+3,21% | 13,68 mld. | |
+33,54% | 12,17 mld. |
- Beurs
- Aandelen
- Koers IDIA
- Onderneming Idorsia Ltd